Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • TA137
  • Published: 
Download guidance (PDF)

Update information

Minor changes after publication

February 2014: Implementation section updated to clarify that rituximab is recommended as an option for treating relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma.

ISBN: 978-1-4731-7077-3